Crossword for strong solvers seems to be the best strategy choice vaccination the general population with booster dose per COVID-19 autumn. UK approval of the first updated booster vaccine targeting the parent virus and the first Variant “Omicron”strengthened the general reflection on what should be done in the coming months.

The US and European authorities seem to be taking a different line, waiting for the next updated vaccines to cover the options currently prevailing. “Omicron” BA.4 and “Omicron” BA.5. Until they are approved, new options may emerge. This role is already claimed by the BA.2.75 or “Centaur” variant, which has been identified in at least 25 countries, including 10 in Europe. Specialist scientists believe that the selection of a variant in our country is only a matter of time.

Confusion in anticipation of the next formulations, which will cover the predominant options “Omicron” BA.4 and “Omicron” BA.5.

“Coronavirus is one step ahead of vaccines. Decisions about when to give the fourth dose of the COVID-19 vaccine should not depend on when we have an updated vaccine. We must accept them based on what we already know. And at some point, a new vaccine will come into the equation.” accent on “k” Professor of Pharmacology, Pharmacogenomics and Precision Medicine, Director of the Pharmacological Laboratory of the Democritus University in Alexandroupolis, Evangelos Manolopoulos. “We need to know that existing vaccines protect against serious diseases. The updated vaccines will produce more antibodies to reduce the chance of initial infection, but they are not expected to have much of an advantage in controlling severe disease.”

According to the professor, at this stage, two updated vaccines. The one approved in the UK provides protection against both the original Omicron and an updated vaccine that is being tested and targets both Omicron BA.4 and BA.5. “The first one is already obsolete due to the development of the pandemic,” the professor notes and continues: “With this reasoning FDA (US Food and Drug Administration) about a month ago banned companies from filing applications for registration of this vaccine, requiring them to prepare a vaccine against BA.4 and BA.5. To everyone’s surprise, the UK, where they applied, approved it. However, the European Union seems to be following the US strategy. The BA.4 and BA.5 vaccines are expected to be submitted to regulatory authorities for approval in October. In any case, this is not a reason to wait two or even three months to get vaccinated.”